Onconova Therapeutics, Inc.
ONTX
ONTX: Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
moreShow ONTX Financials
Recent trades of ONTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ONTX's directors and management
Government lobbying spending instances
-
$10,000 Apr 20, 2016 Issue: Defense
-
$10,000 Apr 17, 2015 Issue: Defense
-
$10,000 Apr 11, 2013 Issue: Defense
-
$10,000 Apr 19, 2012 Issue: Defense
-
$10,000 Jul 19, 2011 Issue: Defense
-
$10,000 Apr 19, 2011 Issue: Defense
-
$10,000 Apr 16, 2010 Issue: Defense
-
$40,000 Jan 20, 2010 Issue: Defense
-
$20,000 Oct 19, 2009 Issue: Defense
-
$20,000 Jul 21, 2009 Issue: Defense
-
$20,000 Apr 20, 2009 Issue: Defense
-
$40,000 Jan 21, 2009 Issue: Defense
-
$20,000 Jul 21, 2008 Issue: Defense
-
$20,000 Apr 21, 2008 Issue: Defense
-
$10,000 Apr 18, 2008 Issue: Defense
-
$40,000 Feb 14, 2008 Issue: Defense
-
$40,000 Feb 11, 2008 Issue: Defense
-
$40,000 Aug 14, 2007 Issue: Defense
-
$40,000 Aug 09, 2007 Issue: Defense
-
$40,000 Feb 26, 2007 Issue: Defense
-
$40,000 Feb 12, 2007 Issue: Defense
-
$80,000 Aug 24, 2006 Issue: Defense
-
$40,000 Aug 10, 2006 Issue: Defense
-
$40,000 Feb 14, 2006 Issue: Defense
-
$40,000 Aug 15, 2005 Issue: Defense
-
$40,000 Aug 10, 2005 Issue: Defense
-
$40,000 Aug 03, 2005 Issue: Defense
-
$40,000 Feb 14, 2005 Issue: Defense
-
$40,000 Aug 13, 2004 Issue: Defense
-
$45,000 Mar 25, 2004 Issue: Defense
-
$40,000 Feb 17, 2004 Issue: Defense
-
$40,000 Jan 29, 2004 Issue: Defense
-
$40,000 Aug 14, 2003 Issue: Defense
-
$20,000 Feb 14, 2003 Issue: Health Issues Defense
-
$40,000 Jan 02, 2003 Issue: Defense Health Issues
-
$40,000 Aug 13, 2002 Issue: None
-
$20,000 Aug 08, 2002 Issue: Defense Health Issues
New patents grants
-
Patent Title: Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability Jul. 12, 2022
-
Patent Title: Methods and compositions for treatment of cancer Mar. 03, 2020
-
Patent Title: Formulations with enhanced stability and bioavailability for administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones Oct. 16, 2018
-
Patent Title: Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone Jul. 25, 2017
-
Patent Title: Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone Jun. 23, 2015
-
Patent Title: Compositions and methods for prevention and treatment of wounds Jun. 02, 2015
-
Patent Title: Formulations for parenteral administration of amino-substituted (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones Jul. 02, 2013
-
Patent Title: Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions Sep. 25, 2012
-
Patent Title: Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones Nov. 22, 2011
Federal grants, loans, and purchases
Followers on ONTX's company Twitter account
Number of mentions of ONTX in WallStreetBets Daily Discussion
Recent insights relating to ONTX
Recent picks made for ONTX stock on CNBC
ETFs with the largest estimated holdings in ONTX
Flights by private jets registered to ONTX